Goldman Sachs Resumes Express Scripts (ESRX) at Conviction Buy

Article Stock Quotes (1) Comments (0)

Goldman Sachs resumes coverage on Express Scripts (NASDAQ: ESRX) with a Conviction Buy rating and $70 price target, suggesting 26% following approval of the Medco merger.

The firm notes that with the merger Express Scripts becomes a top 10 US HC company (market cap) growing EPS over 20% on average through 2015.

Goldman said catalysts included: 22% three-year EPS CAGR, a robust 2013 selling season, as generics and mail benefit slows Express' unmatched scale and specialty capabilities will drive earnings.

For an analyst ratings summary and ratings history on Express Scripts click here. For more ratings news on Express Scripts click here.

Shares of Express Scripts closed at $55.50 yesterday, with a 52 week range of $34.47-$60.89.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
• Singh's TPG-Axon Shows New Stake in Agilent (A), Express Scripts (ESRX), FMC (FMC) (more...)
• Goldman Sachs Upgrades Ruckus Wireless (RKUS) to Buy, 'Pullback Creates Opportunity'

Create E-mail Alert Related Categories

New Coverage

Related Entities

Goldman Sachs, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?